Rapport Therapeutics (RAPP) Cash & Equivalents (2023 - 2026)
Rapport Therapeutics (RAPP) recorded Cash & Equivalents of $63.61 million in Q2 2026, up 15.5% from $55.07 million a year earlier but down 18.5% from the prior quarter.
Powered by 
Analysis
Rapport Therapeutics (RAPP) Cash & Equivalents (2023 - 2026) Analysis & Trends
At the end of FY2025, Rapport Therapeutics reported Cash & Equivalents of $52.65 million, down 7.3% from FY2024.
- Across earlier years, Cash & Equivalents came in at $56.81 million in FY2024 (-19.0%) and $70.17 million in FY2023.
- Quarterly Cash & Equivalents has ranged from $39.31 million in Q3 2024 to $251.36 million in Q3 2025 over the past five years.
- On a year-over-year basis, Cash & Equivalents rose in three of the last eight quarters, with growth averaging 52.0%.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 539.4% in Q3 2025, against a decline of 75.3% in Q3 2024 at the low end.
- Per Business Quant, the preceding three quarters came in at $78.06 million (Q1 2026), $52.65 million (Q4 2025) and $251.36 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Rapport Therapeutics | 1.57 Bn | 1.57 Bn | - | 63.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 63.61 Mn |
| Mar 31, 2026 | 78.06 Mn |
| Dec 31, 2025 | 52.65 Mn |
| Sep 30, 2025 | 251.36 Mn |
| Jun 30, 2025 | 55.07 Mn |
| Mar 31, 2025 | 57.60 Mn |
| Dec 31, 2024 | 56.81 Mn |
| Sep 30, 2024 | 39.31 Mn |
| Jun 30, 2024 | 110.16 Mn |
| Mar 31, 2024 | 74.27 Mn |
| Dec 31, 2023 | 70.17 Mn |
| Sep 30, 2023 | 159.41 Mn |
| Jun 30, 2023 | 79.53 Mn |
API Access
Rapport Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RAPP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "RAPP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RAPP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();